Ildong Pharmaceutical said it has completed a phase 2/3 trial of Xocova (pipeline name: S-217622), an oral Covid-19 treatment candidate, in Korea.In a public filing on Friday, the company said it ended the phase 2/3 trial of S-217622 in patients infected with SARS-CoV-2 and submitted the clinical st
Yuhan Corp.’s degenerative disc treatment Remedisc (pipeline name in Korea: YH14618), licensed to an American pharmaceutical firm, entered a phase 3 trial in the U.S.On Friday, Yuhan announced that the first patient received YH14618 in the phase 3 study in the U.S.Yuhan’s partner, Spine BioPharma, c
Ildong Pharmaceutical successfully registered a patent on Reyvow Tab. (ingredient: lasmiditan hemisuccinate), a migraine treatment, blocking a possible market entry by a latecomer drugmaker.On Aug. 5, the Ministry of Food and Drug Safety (MFDS) put Ildong’s Reyvow Tab. 100mg and Reyvow Tab. 50mg on
Aston Science said on Wednesday that it obtained approval from the U.S. Food and Drug Administration for phase 2 clinical trials of its therapeutic cancer vaccine AST-301 on patients with triple-negative breast cancer (TNBC).The company said it confirmed the excellent safety, immunogenicity, and sur
Kangstem Biotech said Wednesday it has confirmed the safety and effectiveness of its atopic dermatitis stem cell treatment, Furestem-AD Inj, in three-year interim results of the long-term study (K0102-E) of phase 3 clinical trials (K0102).The study adhered to the Ministry of Food and Drug Safety gui
Hanmi Science, the holding company of the Hanmi Group, said it would absorb its affiliate Hanmi Healthcare to lead the rapidly changing global healthcare market by acquiring a solid growth engine.Hanmi Science held a board of directors meeting on Tuesday and announced that it had decided to proceed
PharmGen Science said Tuesday that it has secured bioequivalence for 19 ingredients in 29 major products, expecting additional revenue of 20 billion won ($14 million).It said that this additional revenue forecast stems from the government's tightened drug regulations.In June 2020, the government ann
Daewoong Pharmaceutical is expected to start a phase 3 trial of Enavogliflozin (pipeline name: DWP16001), an SGLT-2 inhibitor to treat diabetes, in China in September.According to ClinicalTrials.gov, a registry of clinical trials run by the U.S. National Institutes of Health, information about Daewo
April Bio said Tuesday that it had signed a technology license and joint research and development contract with Yuhan Corp. to develop a new drug candidate.Under the accord, the two companies will conduct joint research to develop a new treatment candidate for a dual- and long-acting fusion protein
Daewoong Pharmaceuticals said on Monday that its potassium-competitive acid blockers (P-CAB)-based drug, Fexuclue (ingredient name: Fexuprazan hydrochloride), received an adaptation certificate for improving gastric mucosal lesions of acute and chronic gastritis.As a result, Fexuclue has secured two
Ildong Pharmaceutical’s oral Covid-19 treatment Xocova (pipeline name: S-217822) will have the first to get Japan’s emergency use authorization (EUA) to score EUA in Korea, an official drug regulator said.As the EUA in Japan is making slow progress, it will be almost impossible to obtain EUA in Kore
Breast cancer patients and their families increasingly demand the government’s quick approval for Enhertu (ingredient: trastuzumab deruxtecan), a new breast cancer treatment.On the online petition site of the National Assembly on Tuesday, a petitioner urged the government to approve Enhertu. It is t
HLB said Friday that the first global clinical phase 3 results of its liver cancer drug, rivoceranib, and camrelizumab, will be presented orally at the proffered paper session of the European Society for Medical Oncology (ESMO) on Sept. 10.Proffered papers are verbally presented in front of experts
Helixmith said Thursday that it has been informed of the recommendation by the Independent Data Monitoring Committee (IDMC) following the panel’s interim analysis of its diabetic peripheral neuropathy (DPN) treatment, Engensis (VM202).The IDMC reviewed the interim analysis data and the results of He
GSK Korea has again set about to reduce its workforce through an early retirement program (ERP).According to industry insiders, GSK recently announced the ERP plan for its sales representatives, saying it would accept applications from Aug. 17-30. It is the third ERP the Korean offshoot of GSK has c
Gilead’s subsidiary Immunomedics, the original developer of a new anticancer drug Trodelvy (ingredient: sacituzumab govitecan), retrieved its sales rights in Asia from Everest Medicines. The move gives Gilead the sales right of Trodelvy in the global market, including Korea.Everest Medicines Korea,
Genexine said on Tuesday that it has completed the first patient dosing of the triple combination DNA cancer vaccine therapeutic for phase 2 trials.Genexine will combine its GX-188E and GX-I7 with BMS’ global immuno-anticancer drug Opdivo in the clinical trial. Professor Kim Hye-ryun of Yonsei Cance
Hanmi Pharmaceutical said it would begin a local phase 3 trial of poziotinib to treat a certain type of non-small cell lung cancer (NSCLC). Attention is on whether the drugmaker will complete the confirmatory trial, a condition required by the U.S. FDA to obtain marketing approval.On Tuesday, the Mi
Samsung Life Science Fund said on Wednesday that it would invest $15 million (19 billion won) in Senda Biosciences, a U.S. biotech company specializing in natural nanoparticle-based drug delivery technology, to develop next-generation biopharmaceuticals.Senda is a merger of four natural nanoparticle
Novartis Korea said Beovu (ingredient: brolucizumab), a treatment for wet, age-related macular degeneration (AMD), obtained the Ministry of Food and Drug Safety approval for expanded indication to also treat diabetic macular edema on Aug. 4.The ministry granted the expanded indication approval based